Telomir Pharmaceuticals Secures $1 Million Equity Funding at Premium

Telomir Pharmaceuticals, Inc., a company pioneering in age-reversal science, announced a $1 million investment from The Starwood Trust. The deal, set at $7 per share, represents a 20% premium to the closing price and includes no warrants. This follows a $5 million non-dilutive credit line secured earlier in the year from the same partner, further solidifying Telomir's financial strategy.

The funding supports Telomir's initiatives towards advancing Telomir-1, their lead compound targeting chronic diseases and aging. Recent preclinical results suggest Telomir-1 may reverse aging effects and tackle Type 2 diabetes at its root cause, showing potential across various age-related conditions.

Erez Aminov, CEO, emphasizes the strength of their financial strategy and the promising preclinical outcomes. Telomir aims to expand research on therapies for conditions ranging from Alzheimer's to cancer, emphasizing a commitment to innovative healthcare solutions.